POAI vs. NXL, COCH, SURG, POCI, IRIX, DRIO, XAIR, PTHL, CODX, and BSGM
Should you be buying Predictive Oncology stock or one of its competitors? The main competitors of Predictive Oncology include Nexalin Technology (NXL), Envoy Medical (COCH), SurgePays (SURG), Precision Optics (POCI), IRIDEX (IRIX), DarioHealth (DRIO), Beyond Air (XAIR), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), Co-Diagnostics (CODX), and BioSig Technologies (BSGM). These companies are all part of the "medical equipment" industry.
Predictive Oncology vs.
Predictive Oncology (NASDAQ:POAI) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.
Nexalin Technology has lower revenue, but higher earnings than Predictive Oncology. Nexalin Technology is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.
Predictive Oncology received 148 more outperform votes than Nexalin Technology when rated by MarketBeat users. Likewise, 64.22% of users gave Predictive Oncology an outperform vote while only 50.00% of users gave Nexalin Technology an outperform vote.
Predictive Oncology has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.24, suggesting that its stock price is 324% more volatile than the S&P 500.
Predictive Oncology currently has a consensus target price of $3.00, suggesting a potential upside of 139.04%. Nexalin Technology has a consensus target price of $3.00, suggesting a potential upside of 0.84%. Given Predictive Oncology's higher probable upside, equities research analysts clearly believe Predictive Oncology is more favorable than Nexalin Technology.
Predictive Oncology has a net margin of -1,012.32% compared to Nexalin Technology's net margin of -3,407.98%. Nexalin Technology's return on equity of -187.59% beat Predictive Oncology's return on equity.
In the previous week, Predictive Oncology had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 4 mentions for Predictive Oncology and 2 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.00 beat Predictive Oncology's score of -0.35 indicating that Nexalin Technology is being referred to more favorably in the news media.
9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 3.4% of Predictive Oncology shares are held by insiders. Comparatively, 24.0% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Predictive Oncology beats Nexalin Technology on 9 of the 16 factors compared between the two stocks.
Get Predictive Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Predictive Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:POAI) was last updated on 1/21/2025 by MarketBeat.com Staff
